Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 1, 2010, Pages 152-160

  Salvatore, Christopher A ^a   Moore, Eric L ^a   Calamari, Amy ^a   Cook, Jacquelynn J ^a   Michener, Maria S ^a   O'Malley, Stacey ^a   Miller, Patricia J ^a   Sur, Cyrille ^a   Williams Jr , David L ^a   Zeng, Zhizhen ^a   Danziger, Andrew ^a   Lynch, Joseph J ^a   Regan, Christopher P ^a   Fay, John F ^a   Tang, Yui S ^a   Li, Chi Chung ^a   Pudvah, Nicole T ^a   White, Rebecca B ^a   Bell, Ian M ^a   Gallicchio, Steven N ^a   Graham, Samuel L ^a   Selnick, Harold G ^a   Vacca, Joseph P ^a   Kane, Stefanie A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(8) 8 (3,5 DIFLUOROPHENYL) 10 OXO 6,9 DIAZASPIRO[4.5]DEC 9 YL] N [(2) 2' OXO 1,1',2',3 TETRAHYDROSPIRO[INDENE 2,3' PYRROLO[2,3 B]PYRIDIN] 5 YL]ACETAMIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CAPSAICIN; MK 3207; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUDIOGRAPHY; BINDING AFFINITY; BRAIN SLICE; BRAIN STEM; CEREBELLUM; CEREBROSPINAL FLUID; CISTERNA MAGNA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EMBRYO; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LASER DOPPLER FLOWMETRY; MALE; MENINX; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RHESUS MONKEY; RODENT; SKIN BLOOD FLOW; VASODILATATION;

ANIMALS; AUTORADIOGRAPHY; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; BRAIN; CELL LINE; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; KINETICS; MACACA MULATTA; MALE; MICE; P-GLYCOPROTEIN; RADIOLIGAND ASSAY; RECEPTORS, CALCITONIN; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RECEPTORS, PEPTIDE; SPIRO COMPOUNDS; VASODILATION;

EID: 77949687406     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.163816     Document Type: Article

References (41)

1. Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS, and Goadsby PJ (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62:1270-1275.
2. Amara SG, Jonas V, Rosenfeld MG, Ong ES, and Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244.
3. Bell IM, Gallicchio SN, Wood MR, Quigley AG, Stump CA, Zartman CB, Fay JF, Li C, Lynch JL, Moore EL, et al. (2010) Discovery of 2-[(8R)-8-(3,5- difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R) -2′-oxo-1,1′,2′, 3-tetrahydrospiro[indene-2,3′- pyrrolo[2,3-b]pyridin]-5-yl]acetamide (MK-3207): a highly potent, orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist. ACS Med Chem Lett doi:10.1021/ml900016y.
4. Caron KM and Smithies O (2001) Extreme hydrop fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A 98:615-619.
5. Christopoulos G, Paxinos G, Huang XF, Beaumont K, Toga AW, and Sexton PM (1995) Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 73:1037-1041.
6. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, and Sexton PM (1999) Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56:235-242.
7. Dackor R, Fritz-Six K, Smithies O, and Caron K (2007) Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem 282:18094-18099.
8. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, and Eberlein W (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420-423.
9. Edvinsson L, Sams A, Jansen-Olesen I, Tajti J, Kane SA, Rutledge RZ, Koblan KS, Hill RG, and Longmore J (2001) Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol 415:39-44.
10. Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR, and Dickerson IM (2000) CGRPRCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 275:31438-31443.
11. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, and Palumbo R (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384-390.
12. Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cook JJ, and Motzel SL (2003) An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci 42:53-59.
13. Goadsby PJ and Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56.
14. Goadsby PJ, Edvinsson L, and Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28: 183-187.
15. Hasbak P, Sams A, Schifter S, Longmore J, and Edvinsson L (2001) CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1′ (W098/11128), a non-peptide antagonist. Br J Pharmacol 133:1405-1413.
16. Hershey JC, Corcoran HA, Baskin EP, Salvatore CA, Mosser S, Williams TM, Koblan KS, Hargreaves RJ, and Kane SA (2005) Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 127:71-77.
17. Hewitt D, Aurora S, Dodick D, Goadsby P, Ge J, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, et al. (2009) Efficacy and tolerability of the CGRP receptor antagonist MK-3207 for the acute treatment of migraine: a single attack randomized double-blind placebo-controlled adaptive dose ranging trial. Cephalalgia 29: 1350-1351.
18. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, et al. (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115- 2123.
19. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T, Koyama T, Fukuchi J, Iimuro S, Moriyama N, et al. (2008) The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 118:29-39.
20. Lassen LH, Jacobsen VB, Petersen P, Sperling B, Iversen HK, and Olesen J (1998) Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs. Eur J Neurol 5:S63.
21. Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, and Messlinger K (2008) Calcitonin receptor-like receptor (CLR), receptor activitymodifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507:1277-1299.
22. Levy D, Burstein R, and Strassman AM (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698-705.
23. Lynch JJ, Regan CP, Edvinsson L, Hargreaves RJ, and Kane SA (2010) Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol doi:10.1097/FJC. 0b013e3181d7665f.
24. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, and Kane SA (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 277:14294-14298.
25. 2C receptors. Neuroscience 148:250-265.
26. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339.
27. Miller PS, Barwell J, Poyner DR, Wigglesworth MJ, Garland SL, and Donnelly D (2009) Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochem Biophys Res Commun 391:437-442.
28. Moore EL, Burgey CS, Paone DV, Shaw AW, Tang YS, Kane SA, and Salvatore CA (2009) Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine. Eur J Pharmacol 602:250-254.
29. Muff R, Bühlmann N, Fischer JA, and Born W (1999) An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140:2924-2927.
30. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, and BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110.
31. Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, Koblan KS, Salvatore CA, Mosser SD, Johnston VK, et al. (2007) Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2- oxo-1-(2,2,2-trifluoroethyl) azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem 50:5564-5567.
32. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, and Olesen J (2003) The novel CGRP-antagonist, BIBN4096BS does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia 23:729.
33. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, and Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28:226-236.
34. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, et al. (2008) Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3- difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl) azepan-3-yl]-4-(2-oxo-2,3- dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324:416-421.
35. Salvatore CA, Mallee JJ, Bell IM, Zartman CB, Williams TM, Koblan KS, and Kane SA (2006) Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 45:1881-1887.
36. Semark JE, Middlemiss DN, and Hutson PH (1992) Comparison of calcitonin generelated peptide receptors in rat brain and a human neuroblastoma cell-line SK-N-MC. Mol Neuropharmacol 2:311-317.
37. Sexton PM (1991) Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol 5:251-273.
38. Sexton PM, McKenzie JS, Mason RT, Moseley JM, Martin TJ, and Mendelsohn FA (1986) Localization of binding sites for calcitonin gene-related peptide in rat brain by in vitro autoradiography. Neuroscience 19:1235-1245.
39. Stump CA, Bell IM, Bednar RA, Bruno JG, Fay JF, Gallicchio SN, Johnston VK, Moore EL, Mosser SD, Quigley AG, et al. (2009) The discovery of highly potent CGRP receptor antagonists. Bioorg Med Chem Lett 19:214-217.
40. Sur C, Hargreaves R, Bell I, Dancho M, Graham S, Hostetler E, Kane S, Kim J, Michener M, Miller P, et al. (2009) CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia 29(Suppl 1):136.
41. Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Schayck RV, Coenen HH, and Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658-660.